Locally Advanced Pancreatic Cancer: Reducing Lymphopenia to Improve Outcomes

Lymphopenia—a condition where lymphocyte levels in blood are below normal—is frequently caused by chemoradiation (CRT). Since lymphopenia is associated with worse survival outcomes in patients with cancer, there is a huge need to decrease this condition. Researchers found that in patients with nonmetastatic, unresectable pancreatic ductal adenocarcinoma (PDAC) who have been treated with neoadjuvant 5-fluorouracil (5FU)/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) and CRT, severe lymphopenia ca...
Continue reading

Adjuvant Chemo Improves Survival in Node-Positive Pancreatic Cancer

Pancreatic cancer has a dismal prognosis with a 5-year survival rate of 9%. Even after upfront surgical resection combined with adjuvant chemotherapy, 75% of patients relapse within 2 years. However, results from a recent study show that adjuvant chemotherapy can improve outcomes in patients with pathology-proven node-positive pancreatic cancer who received neoadjuvant folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) and resection, providing a potential new standard of care t...
Continue reading

Olaparib Approval: BRCA-Mutated Metastatic Pancreatic Cancer

The FDA has now approved olaparib (Lynparza®, AstraZeneca) for the maintenance treatment of adults with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma who have not experienced disease progression after at least 16 weeks of a first-line platinum-based chemotherapy regimen. In addition, the FDA approved the BRACAnalysis CDx test (Myriad Genetic Laboratories, Inc.) as a companion diagnostic for the selection of patients with deleterious or suspected ...
Continue reading

Epidermal Growth Factor Ointment for Skin Toxicities: An Interview With Sung Yong Oh, MD, PhD

By inhibiting epidermal growth factor receptor (EGFR) signaling pathways, EGFR inhibitors have shown efficacy in the treatment of a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. However, most patients who receive EGFR inhibitors develop adverse skin events, such as acneiform rash, xerosis, paronychial inflammation, pruritis, photosensitivity, and hair and eyelash alteration. If not properly managed, these toxicities can lead to physic...
Continue reading

Epidermal Growth Factor Ointment Relieves Skin Toxicities

A new study reports that epidermal growth factor (EGF) ointment is effective in managing skin toxicities and improving quality of life in patients treated with epidermal growth factor receptor (EGFR) inhibitors. By inhibiting EGFR signaling pathways, which play a role in the pathogenesis and progression of a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer, EGFR tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies are effective ...
Continue reading

Copyright © 2021 Oncology Data Advisor. All rights reserved.